Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ImageneBio, Inc. (IMA : NSDQ)

• Company Description    Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly known as Ikena Oncology Inc., is based in SAN DIEGO. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $5.56 Daily Weekly Monthly 20 Day Moving Average: 61,938 shares Shares Outstanding: 10.65 (millions) Market Capitalization: $59.24 (millions) Beta: 0.73 52 Week High: $18.00 52 Week Low: $3.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.12% -9.75% 12 Week -18.59% -24.74% Year To Date -19.42% -26.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12526 HIGH BLUFF DRIVE SUITE 345 - SAN DIEGO,CA 92130 USA ph: 858-345-6265 fax: - ir@inmagenebio.com http://www.inmagenebio.com

• General Corporate Information    Officers Kristin Yarema - Chief Executive Officer Jonathan Jian Wang - Chair of the Board Joseph P. Slattery - Director Otello Stampacchia - Director Weiguo Su - Director Peer Information ImageneBio, Inc. (CORR.) ImageneBio, Inc. (RSPI) ImageneBio, Inc. (CGXP) ImageneBio, Inc. (BGEN) ImageneBio, Inc. (GTBP) ImageneBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45175G207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/23/26 Share - Related Items Shares Outstanding: 10.65 Most Recent Split Date: 7.00 (0.08:1) Beta: 0.73 Market Capitalization: $59.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.48 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 56.04% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -38.96 12/31/25 - -37.77 09/30/25 - -92.46 ROA 03/31/26 - -34.60 12/31/25 - -33.56 09/30/25 - -41.44 Current Ratio 03/31/26 - 18.39 12/31/25 - 12.49 09/30/25 - 13.24 Quick Ratio 03/31/26 - 18.39 12/31/25 - 12.49 09/30/25 - 13.24 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - -5,712.38 09/30/25 - - Book Value 03/31/26 - 11.57 12/31/25 - 11.91 09/30/25 - 12.51 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©